budoprutug — Topline data
H2 2026
SLE Phase 1b: initial data, including preliminary efficacy (H2 2026)Source filing
CLYM biotech catalysts & pipeline
CLIMB BIO INC · Data as of 2026-09-08
Upcoming catalysts
budoprutug — Topline data
Late 2026
The Company expects to announce additional data from the study by year-end 2026.Source filing
budoprutug — Initial data
Q4 2026
Anticipate data, including safety and biomarker data from the Global study in the fourth quarter of 2026.Source filing
budoprutug — Initial data
2027
Plan to initiate a multiple-dose study of the SC formulation in autoimmune patients; anticipate initial data in 2027.Source filing
CLYM116 — Initial data
H1 2027
Initial data from NAVIGATE-2 Phase 2 anticipated in the first half of 2027Source filing
CLYM116 — Conference presentation
Q4 2026
Additional data from the ongoing Phase 1 study and initial reporting of Beijing Mabworks Biotech Co., Ltd. (Mabworks) Phase 1 healthy volunteer study in China to be presented at an upcoming medical meeting in the fourth quarter of 2026Source filing